-
Cost-Effectiveness of High-Dose vs. Adjuvanted Trivalent Influenza Vaccines in Older Adults in Korea
Sep 9, 2025, 16:22 PM -
Quantifying the Societal Value: Reduced Burden and Resource Savings From Baloxavir Marboxil's Influenza Transmission Protection in China
Sep 9, 2025, 16:22 PM -
Length of Stay (LOS) and Associated Healthcare Resource Use (HCRU) for a First Infusion of Axi-cel or Lisocel in Second Line for Large B-cell Lymphoma in France: Differences Observed From Comprehensive Hospital Databases
Sep 9, 2025, 16:22 PM -
Beyond Leave-One-Out: A Ranked Leave-k-Out Method for Detecting Influential Studies
Sep 9, 2025, 16:22 PM -
Reevaluating Cost-Effectiveness: A Holistic Framework for Assessing Disease-Modifying Treatments in Type 1 Diabetes
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Ribociclib Plus Endocrine Therapy for the Treatment of HR/HER2 Early Breast Cancer in Greece
Sep 9, 2025, 16:22 PM -
Evaluating an Automated AI-Driven Pipeline for Literature Surveillance and Synthesis: A Proof-of-Concept for Health Economics and Outcomes Research (HEOR) Communications
Sep 9, 2025, 16:22 PM -
Health Technology Assessments of Oncology Orphan and Advanced Therapies: The Case for Incorporating Real-World Evidence Patient-Reported Outcomes and Indirect Treatment Comparisons Into Joint Clinical Assessment Submissions
Sep 9, 2025, 16:22 PM -
A Proof of Concept Study to Build a Japanese-Based Electronic Medical Record Data Model Suited for Real-World Research
Sep 9, 2025, 16:22 PM -
Assessing the Sensitivity of EQ-5D-5L and AQoL-4D to Disease Severity in Von Willebrand Disease: Findings From UK Cohort of the PIVOT-vWD Study
Sep 9, 2025, 16:22 PM -
Impact of Indirect Treatment Comparison (ITC) Methodology on Cost-Effectiveness of Quizartinib in Acute Myeloid Leukemia (AML) in Canada and the United Kingdom (UK)
Sep 9, 2025, 16:22 PM -
Evaluation of Health-Related Quality of Life (HRQoL) Among Patients Treated With Lifileucel After Progression on Immune Checkpoint Inhibitors (ICIs) and Targeted Therapies: Analyses From the C-144-01 Trial
Sep 9, 2025, 16:22 PM -
Improving Patient Flow and Multidisciplinary Coordination in Urothelial Carcinoma: Insights From Bulgarian Oncologists
Sep 9, 2025, 16:22 PM -
Cost per Responder of TAR-200 vs. Other FDA-Approved Novel and Generic Treatments Among Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer With Carcinoma in Situ in the United States
Sep 9, 2025, 16:22 PM -
Safety Profile of Semaglutide in Obesity Management With or Without Type 2 Diabetes (T2DM): A Systematic Literature Review From Controlled and Real-World Settings
Sep 9, 2025, 16:22 PM -
Decoding Atorvastatin-Induced Arthritis: A Systems Pharmacology Approach Integrating Pharmacovigilance, Bioinformatics, and Pathway Enrichment
Sep 9, 2025, 16:22 PM -
Are Glucagon-Like Peptide-1 Receptor Agonists Prescribed for Weight Loss Slipping Through the Net of Japan’s Strict Guidelines? An Analysis of Health Insurance Claims Data
Sep 9, 2025, 16:22 PM -
Reference Framework, Key Decision-Making Factors, and the Impact of Critical Parameters on Listing Recommendations for Nononcologic Drugs for Rare Diseases Issued by Canadian HTA Bodies
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Entrectinib in First-Line Treatment for NTRK Locally Advanced or Metastatic NSCLC in China
Sep 9, 2025, 16:22 PM -
Comparative Health Economic Evaluation of Alzheimer’s Diagnostic Treatment Strategies in the Era of Amyloid-Targeting Therapies: A Conceptual Model Framework
Sep 9, 2025, 16:22 PM
